Breaking News
LAST CHANCE for Cyber Monday SALE: Up to 54% off InvestingPro! Register here
Quotes
All Instrument Types
  • All Instrument Types
  • Indices
  • Equities
  • ETFs
  • Funds
  • Commodities
  • Currencies
  • Crypto
  • Bonds
  • Certificates

Please try another search

Search website for: 
Popular News
More
Popular Analysis
More
More
/Free Sign Up
 Investing Pro 0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details
Close

Genmab (GMAB)

Create Alert
Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Create Manage my alerts 
Back
Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
 
Create New Watchlist Create
Create a new holdings portfolio Add Create
+ Add another position Close
2,550.0 -34.0    -1.32%
15:59:59 - Closed. Currency in DKK ( Disclaimer )
  • Volume: 128,834
  • Bid/Ask: 0.0 / 0.0
  • Day's Range: 2,534.0 - 2,588.0
Type:  Equity
Market:  Denmark
ISIN:  DK0010272202 
S/N:  65702915
Genmab 2,550.0 -34.0 -1.32%

GMAB Income Statement

 
Assess the Genmab income statement, view the company's financial performance across their assets and liabilities. Select to view either quarterly or annual data.
AnnualQuarterly
Collapse All
Period Ending: 2021
30/09
 2021
30/06
 2021
31/03
 2020
31/12
Total Revenue 2310 1972 1581 2044
Revenue 2310 1972 1581 2044
Other Revenue, Total - - - -
Cost of Revenue, Total - - - -
Gross Profit - - - -
Total Operating Expenses 1420 1185 1049 1157
Selling/General/Admin. Expenses, Total 306 264 201 231
Research & Development 1114 921 848 926
Depreciation / Amortization - - - -
Interest Expense (Income) - Net Operating - - - -
Unusual Expense (Income) - - - -
Other Operating Expenses, Total - - - -
Operating Income 890 787 532 887
Interest Income (Expense), Net Non-Operating 281 -365 892 -336
Gain (Loss) on Sale of Assets - - - -
Other, Net - - - -
Net Income Before Taxes 1171 422 1424 551
Provision for Income Taxes 281 116 328 -30
Net Income After Taxes 890 306 1096 581
Minority Interest - - - -
Equity In Affiliates - - - -
U.S GAAP Adjustment - - - -
Net Income Before Extraordinary Items 890 306 1096 581
Total Extraordinary Items - - - -
Net Income 890 306 1096 581
Total Adjustments to Net Income - - - -
Income Available to Common Excluding Extraordinary Items 890 306 1096 581
Dilution Adjustment - - - -
Diluted Net Income 890 306 1096 581
Diluted Weighted Average Shares 66.07 65.95 65.98 66.08
Diluted EPS Excluding Extraordinary Items 13.47 4.64 16.61 8.79
DPS - Common Stock Primary Issue - - - -
Diluted Normalized EPS 13.47 4.64 16.61 8.79
* In Millions of DKK (except for per share items)
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

I Agree

GMAB Comments

Write your thoughts about Genmab
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Cancel Attach
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Confirm Block Cancel
Ok
Report this comment

I feel that this comment is:

Submit
Comment flagged

Thank You!

Your report has been sent to our moderators for review
Close
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email